Acumen Pharmaceuticals Inc.
ABOS | NASDAQ
$2.65
+$0.06 (+2.32%)
Sep 22, 2026, 12:30 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | 1.44M |
Cost of Revenue | n/a | n/a | n/a | n/a | 12.31M | 8M |
Gross Profit | n/a | n/a | n/a | n/a | -12.31M | -6.56M |
Operating Income | -123.83M | -114.02M | -61.14M | -45.24M | -19.58M | -7.91M |
Interest Income | 7.45M | 14.32M | 10.79M | 2.39M | 84K | 1K |
Pretax Income | -121.34M | -102.33M | -52.37M | -42.86M | -100.61M | -7.33M |
Net Income | -121.34M | -102.33M | -52.37M | -42.86M | -100.61M | -7.33M |
Selling & General & Admin | 18.95M | 20.22M | 18.82M | 12.88M | 7.28M | 1.35M |
Research & Development | 104.89M | 93.8M | 42.32M | 32.36M | 12.31M | 8M |
Other Expenses | n/a | n/a | n/a | n/a | -12.31M | -8M |
Operating Expenses | 123.83M | 114.02M | 61.14M | 45.24M | 7.28M | 1.35M |
Interest Expense | 4.22M | 4.07M | 581K | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 123.83M | 114.02M | 61.14M | 45.24M | 19.58M | 9.35M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 60.56M | 60.01M | 48.49M | 40.6M | 38.27M | 28.65M |
Shares Outstanding (Diluted) | 60.56M | 60.01M | 48.61M | 40.6M | 38.27M | 28.65M |
EPS (Basic) | -2 | -1.71 | -1.08 | -1.06 | -2.63 | -0.26 |
EPS (Diluted) | -2 | -1.71 | -1.08 | -1.06 | -2.63 | -0.26 |
EBITDA | -116.93M | -98.08M | -51.61M | -42.69M | -100.6M | -7.91M |
EBIT | -117.11M | -98.26M | -51.79M | -42.86M | -100.61M | -7.91M |
Depreciation & Amortization | 184K | 178K | 184K | 169K | 4K | n/a |
Add to Watchlist
Select watchlists to add or remove ABOS